● Recruiting

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Condition: Non-Hodgkin Lymphoma · Sponsor: Cho Pharma Inc.

PhasePhase 1/Phase 2

Planned participants37

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a 2-part study. Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Part 2/Phase 2a will assess the anticancer activity and safety of CHO-H01 plus lenalidomide in subjects with low-grade relapsed/refractory CD20+ non-Hodgkin's lymphoma.

This description comes directly from the study's public registry record.

Talk to the study team

Tanny Tsao · 886226558059 · tanny.tsao@chopharma.com.tw

Always discuss trial participation with your own doctor first.

Locations (9)

Tri-Service General Hospital - Neihu Branch - Hematology	Taipei, Taipei, Taiwan	Terminated
Taipei Medical University - Shuang Ho Hospital - Oncology	New Taipei City, Taipei Special Municipality, Taiwan	Recruiting
National Taiwan University Hospital Yunlin Branch	Huwei, Taiwan, Taiwan	Recruiting
Chi-Mei Medical Center	Tainan, Taiwan, Taiwan	Recruiting
Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Hematology and Oncology - Hematology and Oncology	Taoyuan, Taoyuan, Taiwan	Terminated
Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology	Kaohsiung City, Taiwan	Recruiting
China Medical University Hospital - Hematology/Oncology - Taichung	Taichung, Taiwan	Recruiting
National Cheng Kung University Hospital - Internal Medicine	Tainan, Taiwan	Terminated
National Taiwan University Hospital - Hematology And Oncology	Taipei, Taiwan	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05950165